AMRX (Amneal Pharmaceuticals) GF Value Rank: 1 (As of Jul. 13, 2026) — 67% Below Median


AMRX Amneal Pharmaceuticals Inc AMRX
56 GF Score
Price $17.01
GF Value $7.58
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Amneal Pharmaceuticals GF Value Rank?

Amneal Pharmaceuticals AMRX -0.06% 56 GF Value Rank is 1 as of Jul. 13, 2026, which is 67% below its 10-year median of 3.00. GuruFocus rates AMRX with a GF Score™ of 56/100 and a GF Value™ of $7.58 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Amneal Pharmaceuticals has the GF Value Rank of 1.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Amneal Pharmaceuticals GF Value Rank Related Terms

AMRX vs INDV, KNSA, LQDA: GF Value Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amneal Pharmaceuticals GF Value Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Amneal Pharmaceuticals's GF Value Rank falls into.


AMRX
56GF Score
Amneal Pharmaceuticals Inc AMRX
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 1 mean?
Amneal Pharmaceuticals (AMRX) has a GF Value Rank of 1 as of Jul. 13, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Amneal Pharmaceuticals and its competitors. This is 67% below median its historical median of 3.00. Over the past decade, Amneal Pharmaceuticals' GF Value Rank has ranged from 1.00 to 10.00.
Is Amneal Pharmaceuticals' GF Value Rank too high?
Amneal Pharmaceuticals' current GF Value Rank of 1 is 67% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Amneal Pharmaceuticals has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' GF Value Rank compare to INDV and KNSA?
Amneal Pharmaceuticals' GF Value Rank of 1 can be compared against companies in the Drug Manufacturers industry. Historically, Amneal Pharmaceuticals' own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Drug Manufacturers company?
A good GF Value Rank depends on the Drug Manufacturers industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Amneal Pharmaceuticals and its competitors. Amneal Pharmaceuticals's current GF Value Rank is 1, which is 67% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.58, compared to a current price of $17.01 — trading 124.4% above its estimated fair value. The current GF Value Rank is 1, which is 67% below median its 10-year median of 3.00. Amneal Pharmaceuticals' overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current GF Value Rank is 1 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?

Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued. The current stock price of $17.01 is trading 124.4% above its estimated GF Value™ of $7.58. GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for AMRX:

  • GF Value Rank: 1 (67% below median its 10-year median of 3.00)
  • GF Value™: $7.58 vs. price of $17.01 (124.4% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amneal Pharmaceuticals Business Description

Other Exchanges 2DT:Germany
Address 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
56GF Score

Get the complete analysis for AMRX

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.01
Price
$7.58
GF Value